Articles On Immutep (ASX:IMM)

Immutep (ASX:IMM; NASDAQ:IMMP), a leading biotechnology firm specialising in LAG-3 immunotherapy, has achieved a significant milestone in its quest to redefine cancer treatment. Today, the company announced positive feedback from the US Foo...

Most investors probably wouldn't relish the idea of buying an ASX share that has already fallen by 77%. The ASX is full of investors who love to 'buy the dip', of course. But there aren't too many investors who would regard a 77% share pric...

The ASX is set to fall when it opens Monday, following Wall Street’s losses Major tech stocks like Nvidia and CrowdStrike saw drops, while crude oil tumbled 3pc President Biden has ended his re-election bid   The ASX200 index is expected...

The ASX200 is set to fall 0.56% after another weak day of trading on US markets. On Friday, US Stocks experienced a second session of losses, with the S&P 500 and the Nasdaq dropping 0.7% and 0.8%, respectively, while the Dow Jones e...

Immutep has received regulatory clearance from the Netherlands for its Phase I clinical trial of IMP761 Alcidion nabs $4m contract in a long-term partnership with Hume Rural Health Alliance   Immutep has clearance for Phase 1 trial Immute...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has run out of steam and is on course to record a decline. At the time of writing, the benchmark index is down 0.2% to 8,002.9 points. Four ASX shares that are not letting that hold...

ASX 200 adds about 60 points after intraday record Nine of 11 sectors higher, IT weighed by US megatech losses Pearl Gull Iron pops on REE in Chile   Local markets surged on Friday following positivity overnight on Wall Street after so...

ASX AI stocks have caught a strong bid in 2024. The artificial intelligence domain has seen tremendous growth, spurred on by the meteoric rise of US tech giants like Nvidia Corp (NASDAQ: NVDA). One Australian tech company is also capturi...

The S&P/ASX 200 Index (ASX: XJO) is having another strong session and is on course to end the week with a big gain. At the time of writing, the benchmark index is up 0.85% to 7,957.3 points. Four ASX shares that are rising more than m...

  To register for today's webinar click here. Immutep (ASX:IMM) has announced positive results from Cohort B of the TACTI-003 Phase IIb trial: Eftilagimod alfa (efti) in combination with KEYTRUDA®. The results demonstrate efficacy as first-...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

  Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Medical Officer Dr Florian Vogl, and Senior Vice President Strategic Development Christian Mueller present on Immutep’s latest clinical results. Key points: Efti in c...

Immutep Ltd (ASX: IMM) shares are ending the week with a bang. In morning trade, the ASX healthcare stock is up 25% to 37 cents. Why is this ASX healthcare stock rocketing? This clinical-stage biotechnology company's shares are taking off t...

Biotechnology company Immutep Ltd (ASX:IMM) which is developing novel LAG-3 immunotherapies for cancer and autoimmune disease, has reported a strong response rate from a trial involving a combination of immunotherapy drugs to treat recurren...

Lendlease Group (ASX: LLC) shares are running in the opposite direction to the rest of the market today. Shares in the embattled real estate investment group are down 1.8% to $5.59 in morning trade. Meanwhile, the S&P/ASX 200 Index...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin An additional news report on the recommendation, valuation, forecast and opinion cha...

Normally, the phrases '40% return' and 'bank shares' aren't uttered in the same sentence. ASX bank shares like National Australia Bank Ltd (ASX: NAB) are known for many things. Fat, fully franked, market-leading dividends would be the obvio...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

BrainChip Holdings Ltd (ASX: BRN) shares were one of the weakest performers on the ASX in FY 2024. In the past 12 months, the ASX AI stock plunged nearly 39% in the red. The company's shares are swapping hands at 22 cents apiece at the t...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another decline. At the time of writing, the benchmark index is down 0.6% to 7,706.4 points. Four ASX shares that are falling more than most today are listed...

Two S&P/ASX 200 Index (ASX: XJO) stocks just scored substantial broker upgrades. One of the companies has already been on a tear over the past year, while the other has struggled. But according to top brokers, the next 12 months could...

The S&P/ASX 200 Index (ASX: XJO) endured a rough start to the trading week this Monday. After ending last week on a positive note, ASX investors clearly woke up on the wro...

The start of the new financial year hasn't brought much joy for the Pilbara Minerals Ltd (ASX: PLS) share price this Monday. In fact, Pilbara Minerals shares are starting FY2025 off at a very low point indeed. Last week, shares of this ASX...

The S&P/ASX 200 Index (ASX: XJO) is having a subdued start to the week. In afternoon trade, the benchmark index is down 0.35% to 7,740.4 points. Four ASX shares that are not letting that hold them back are listed below. Here's why the...

If you've been following me on social media, you'll have noticed my feed take on a decidedly different flavour over the past few days. See, it's the middle of the year – school holidays – and we're off on another family outback road tri...

S&P/ASX 200 Index (ASX: XJO) coal shares are smoking hot today. How hot? Well, at the time of writing, the ASX 200 is down 0.46%. But don't blame the big Aussie coal shares for that retrace. Here's how these three leading coal stocks a...

Lendlease Group (ASX: LLC) shares are starting the week positively. In morning trade, the ASX 200 share is up 1.5% to $5.49. Why is this ASX 200 share pushing higher today? Investors have been buying Lendlease shares after it entered into a...

Although the returns on offer with term deposits are the best they have been in years, and could yet improve further if the RBA lifts rates again, they still pale in comparison to what's available from ASX dividend shares. For example, the...

ASX health stocks rise in past five days, despite May uptick in inflation  Healius downgrades guidance for FY24, citing inflationary pressures Immutep falls despite positive results from Phase 2 trial in first line head and neck cancer He...

ASX All Ords healthcare stock Immutep Ltd (ASX: IMM) is down by 26% over the past two days, and one market analyst reckons it's a golden buy-the-dip opportunity staring us right in the face. Immutep shares are currently trading for 32 c...

S&P/ASX 200 Index (ASX: XJO) stocks, taken together, moved higher in June. In afternoon trade on Friday, with just hours left before the ASX closes shop for the month, the benchmark index is up 1.4% since the closing bell rang on 31 Ma...

The S&P/ASX 200 Index (ASX: XJO) is having a better session on Friday. In afternoon trade, the benchmark index is up a solid 0.65% to 7,811.1 points. Four ASX shares that have failed to follow the market higher today are listed below....

Sometimes, people like me can make investing seem way too complicated. Hopefully not me, personally – over the last dozen years of my professional life, I've aimed to make investing as simple as possible for our readers and members – bu...

FleetPartners Group Ltd (ASX: FPR) shares are trading 3% higher in morning trade on Friday after it was confirmed Mitsubishi Motors has acquired a 5% stake in the company. The Japanese automotive giant announced on Monday that it has a...

Fortunately for income investors, the Australian share market is one of the most generous in the world when it comes to dividends. Year in, year out, countless ASX listed companies share a portion of their profits with their lucky sharehold...

The rate of inflation in Australia continues to be stronger than what the Reserve Bank of Australia (RBA) would like, which may have a negative knock-on effect on ASX shares. The latest monthly reading showed that inflation had accelerated...

ASX200 falls fast for a second session after inflation steals the air in the room 7 of 11 ASX sectors lower, with InfoTech the only standout in the plus column Small caps led by Iris Metals and Bellavista Resources   Local markets have...

While the market closed in the red on a down day for the ASX, it wasn’t as bad as futures had predicted after the bourse pared intraday losses. All eyes will be on the US tonight. At 10:30 PM Sydney time, the US will release data on man...

When you first start out investing, you can invest in fledgling growth stocks and small caps. That's because if things don't go quite to plan, you have plenty of time to recoup your losses. However, if you're already in retirement, you cann...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a disappointing decline. At the time of writing, the benchmark index is down 1% to 7,704.4 points. Four ASX shares that are falling more than most today are li...

Immutep sinks 35pc despite positive TACTI-003 Phase IIb trial results Investors may have had higher expectations, leading to the market reaction The trial evaluated efti with KEYTRUDA for first-line head and neck cancer   Immutep (ASX:IMM...

Clinical-stage biotechnology company Immutep (ASX: IMM) has released top-line results from a Phase IIb trial evaluating eftilagimod alfa (efti) in combination with anti-PD-1 therapy KEYTRUDA (pembrolizumab) as a first-line treatment for rec...

Immutep Ltd (ASX: IMM) shares are having a day to forget on Thursday. In morning trade, the ASX healthcare stock is down a whopping 47% to a 52-week low of 23 cents. Why is this ASX healthcare stock crashing? Investors have been racing to t...

  Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific Officer Professor Frédéric Triebel, Chief Medical Officer Dr Florian Vogl, and Senior Vice President Strategic Development Christian Mueller present on Immu...

ASX to fall by 1pc when the market opens Amazon reaches $2 trillion market cap for the first time Aussie property market to remain strong in 2024   The ASX 200 is poised to fall sharply when the market opens on Thursday despite rallies in...

BrainChip Holdings Ltd (ASX: BRN) shares have had a turbulent first half of the year. Despite showing a 16% gain this year to date, nearly all of this occurred in the first two months of the year. After reaching a 52-week high of 54 cent...

Every investor has a different risk appetite. Some investors play it safe and buy low risk, defensive ASX stocks. Others are willing to risk a little for stronger potential returns. And a handful will seek the huge potential returns on offe...

Goldman Sachs is one of the most highly respected investment banks out there. Its analysts scour the globe for investment opportunities and then recommend them to investors. While the broker has buy ratings on a number of ASX shares, it has...

The ASX200 closed up 0.4% – thanks to a very small rise in Australia’s latest Gross Domestic Product data. Quarterly GDP rose just 0.1%, which is the slowest pace of GDP growth in one-and-a-half-years.  As far as the sectors went toda...

Aussie shares rise in arvo trade Resources sectors weigh, Real Estate adds 2pc GDP lowest in 40 years ex. COVID   The local bourse has come home with a sail wet on Wednesday with the ordinariness of our economy bringing market joy as it d...